Cardiovascular diseases remain one of the leading contributors to the global disease burden, encompassing conditions such as myocardial infarction, stroke, and various forms of arrhythmia.

Among these, atrial fibrillation (AF) stands out as the most prevalent type of arrhythmia, affecting over 4% of the global population. As the global population ages, the incidence of AF continues to rise. Critically, AF is associated with a fivefold increase in the risk of stroke, significantly contributing to increased morbidity and mortality.

Traditionally, AF is diagnosed using an electrocardiogram (ECG), which detects irregularities in heart rhythm intervals. However, with the advancement of digital health technologies, photoplethysmography (PPG) has emerged as a promising alternative for monitoring cardiac rhythms. While PPG is a validated tool for detecting AF, its accuracy in assessing heart rate variability has been a subject of ongoing evaluation.

FibriCheck is a healthcare technology company that has developed a clinically validated, FDA-cleared solution that leverages PPG technology to detect and monitor atrial fibrillation. The FibriCheck mobile application enables users to record heart rhythm by simply placing a finger over their smartphone’s camera. Backed by peer-reviewed studies, FibriCheck reports a clinical accuracy rate exceeding 98%, positioning it as a reliable and scalable solution for remote cardiac monitoring.